Partnering Opportunities

ViroStatics is committed to leveraging its AV-HALT program through the establishment of strategic alliances and licensing.  With offices in Sassari, Italy and Princeton, New Jersey, USA, ViroStatics continues the international approach to combating disease of our corporate parent, the Research Institute for Genetic and Human Therapy (RIGHT).

ViroStatics is developing novel therapeutics in the fields of chronic, life-threatening infections that both improve immune function and suppress pathogen replication.  In addition, we have developed innovative biomarker assays of immune system response to immunotherapeutics and vaccines.

We seek to partner with both companies and academia to maximize the value of these assets.

Screening for New AV-HALT Compounds

Utilizing the data and know-how that we have accumulated through our VS411 clinical studies, we have developed a proprietary multi-parameter screening process for the identification of second-generation AV-HALTs combining the class’ two modes of action in a single molecule.

We are interested in working with companies and academia to determine if there may be significant added value within their portfolios in the treatment of HIV/AIDS by determining whether their portfolios contain potential AV-HALT compounds.  We would like to explore establishing potential in-licensing and collaboration arrangements with companies and academia to fully characterize their candidate compounds utilizing our proprietary screening methodologies, potentially leading to the development of the candidate as an AV-HALT medication in the treatment of HIV/AIDS and/or other chronic diseases.

Based on the underlying AV-HALT antiproliferative mechanism of action, compounds originally developed as potential antineoplastic or immunomodulating drugs may be ideal candidates for our proprietary AV-HALT screening program.

Commercialization of Diagnostic Assays

ViroStatics has developed novel biomarkers and immunological assays to document beneficial changes in key immunological responses against viral pathogens during therapy. One such test, the PHPC assay for memory T cells with high proliferative capacity, has demonstrated that increased numbers of these functional T cells correlates with the immune system's ability to control HIV replication. The test holds promise as a tool to evaluate immunotherapies (such as AV-HALTs and targeted immune amplification strategies) in the treatment of HIV/AIDS and other chronic diseases. The Company is looking to partner to successfully commercialize our novel diagnostic assays.


Established Partnerships

Vichem Chemie Collaboration

ViroStatics has formed a strategic partnership with Vichem Chemie an Hungarian biotech research company focusing on the field of kinase inhibitors, to identify and develop second-generation single-molecule AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs) for the treatment of HIV/AIDS and other chronic diseases.

University of Siena Compound Library

ViroStatics has obtained an exclusive license to a focused compound library developed by Professor Maurizio Botta (University of Siena) in collaboration with Professors Silvia Schenone (University of Genova) and Giovanni Maga (IGM-CNR, Pavia). The library consists of specifically designed molecules targeting key cellular enzymes.

For more information, please contact:

James Chafouleas, PhD
Chief Business Development Officer
j.chafouleas@virostatics.com